AR055561A1 - Comprimidos con dispersion mejorada de la sustancia farmacologica - Google Patents

Comprimidos con dispersion mejorada de la sustancia farmacologica

Info

Publication number
AR055561A1
AR055561A1 ARP060100652A ARP060100652A AR055561A1 AR 055561 A1 AR055561 A1 AR 055561A1 AR P060100652 A ARP060100652 A AR P060100652A AR P060100652 A ARP060100652 A AR P060100652A AR 055561 A1 AR055561 A1 AR 055561A1
Authority
AR
Argentina
Prior art keywords
tablets
pharmacological substance
dispersion
preparation
improved dispersion
Prior art date
Application number
ARP060100652A
Other languages
English (en)
Inventor
Synese Jolidon
Robert Narquizian
Roger David Norcross
Emmanuel Pinard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36406213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055561(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR055561A1 publication Critical patent/AR055561A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Abstract

Método para la preparacion de composiciones farmacéuticas en forma de comprimidos con dispersion mejorada de la sustancia farmacologica, caracterizándose dicho método en que comprende los pasos de: a) preparacion de una dispersion en un líquido de al menos una sustancia farmacologica activa y al menos un surfactante y/o enlazante b) preparacion de un transportador mediante mezcla seca de uno o más excipientes(s) incluyendo al menos un transportador poroso; y c) granulado por pulverizacion de la dispersion preparada en a) en un transportador preparado en b) para obtener un producto granulado por pulverizacion.
ARP060100652A 2005-02-25 2006-02-23 Comprimidos con dispersion mejorada de la sustancia farmacologica AR055561A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05101458 2005-02-25

Publications (1)

Publication Number Publication Date
AR055561A1 true AR055561A1 (es) 2007-08-22

Family

ID=36406213

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100652A AR055561A1 (es) 2005-02-25 2006-02-23 Comprimidos con dispersion mejorada de la sustancia farmacologica

Country Status (20)

Country Link
US (2) US20060193910A1 (es)
EP (2) EP1855655A2 (es)
JP (1) JP2008531509A (es)
KR (1) KR20070094666A (es)
CN (1) CN101128189A (es)
AR (1) AR055561A1 (es)
AU (1) AU2006218193A1 (es)
BR (1) BRPI0606187A2 (es)
CA (1) CA2598762A1 (es)
CR (1) CR9292A (es)
IL (1) IL185011A0 (es)
MA (1) MA29268B1 (es)
MX (1) MX2007009571A (es)
NO (1) NO20074092L (es)
NZ (1) NZ560232A (es)
RU (1) RU2007129642A (es)
TW (1) TW200640502A (es)
UA (1) UA90708C2 (es)
WO (1) WO2006089674A2 (es)
ZA (1) ZA200706495B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20090196923A1 (en) * 2006-04-26 2009-08-06 Jayanta Kumar Mandal Controlled release formulation comprising anti-epileptic drugs
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
US20110092598A1 (en) * 2007-10-10 2011-04-21 Nandu Deorkar Driectly Compressible High Functionality Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
CA2748896C (en) * 2009-01-23 2017-01-03 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising aleglitazar
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
CN102641302B (zh) * 2011-02-18 2016-01-20 上海张江中药现代制剂技术工程研究中心 一种提高中药提取物浸膏粉软化点的方法
RU2468789C1 (ru) * 2011-05-04 2012-12-10 Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук (ИрИХ СО РАН) Средство для профилактики и лечения атеросклероза
CN104784239B (zh) * 2015-04-28 2017-12-26 新乡医学院第一附属医院 一种快速溶出的珍菊降压片及其制备工艺
WO2017003137A1 (ko) * 2015-06-30 2017-01-05 (주)아모레퍼시픽 속붕해형 과립환 모발 세정용 조성물
KR20170003414A (ko) * 2015-06-30 2017-01-09 (주)아모레퍼시픽 속붕해형 과립환 모발 세정용 조성물
TN2019000148A1 (en) 2016-11-16 2020-10-05 Abide Therapeutics Inc Pharmaceutical formulations
CN109701441B (zh) * 2018-12-16 2021-04-09 桂林理工大学 一种卵磷脂选择性改性高岭石的制备方法及其应用
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
CN111548218A (zh) * 2020-04-27 2020-08-18 上海应用技术大学 一种通用型花肥速释片及其制备方法和应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2106861C1 (ru) * 1991-01-30 1998-03-20 Дзе Веллкам Фаундейшн Лимитед Диспергируемые в воде таблетки, способ их получения, гранулы и диспергирующий агент для получения таблеток
DE69231395T3 (de) 1991-09-20 2005-07-21 Glaxo Group Ltd., Greenford Neue medizinische Indikation für Tachykinin-Antagonisten
DK0782449T3 (da) * 1994-09-22 2003-08-04 Akzo Nobel Nv Fremgangsmåde til fremstilling af doseringsenheder ved vådgranulering
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
WO1998024441A1 (en) 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety
JP2001504847A (ja) 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 重抑鬱障害の治療のためのnk−1受容体拮抗薬の使用
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
JP4367723B2 (ja) * 1997-08-25 2009-11-18 大正製薬株式会社 水難溶性成分を配合した固形剤
GB9825242D0 (en) 1998-11-19 1999-01-13 Cambridge Advanced Tech Genetically modified plants with altered starch
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
EP1394150B1 (en) 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
DE60015089T2 (de) 1999-02-24 2006-02-16 F. Hoffmann-La Roche Ag 3-phenylpyridinderivative und deren verwendung als nk-1 rezeptorantagonisten
BR0008489A (pt) 1999-02-24 2002-02-05 Hoffmann La Roche Derivados de fenil- e piridinila
ATE278783T1 (de) 1999-03-06 2004-10-15 Roche Diagnostics Gmbh Dna polymerase aus i(pyrobaculum islandicum)
JO2308B1 (en) 1999-05-31 2005-09-12 اف. هوفمان- لاروش أيه جي‏ Derivatives of phenylpyrmidine
US6274588B1 (en) 1999-05-31 2001-08-14 Hoffmann-La Roche Inc. 4-phenyl-pyrimidine derivatives
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
SI1103545T1 (en) 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US6452001B2 (en) 2000-05-25 2002-09-17 Hoffmann-La Roche Inc. Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
ATE400556T1 (de) 2000-07-14 2008-07-15 Hoffmann La Roche N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
YU39503A (sh) 2000-11-22 2006-05-25 F. Hoffmann-La Roche Ag. Derivati pirimidina
EP1349541B1 (en) 2000-12-14 2006-10-04 F. Hoffman-la Roche AG Self emulsifying lipid matrix (selm)
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
EP1385577B1 (en) 2001-04-23 2006-04-19 F. Hoffman-la Roche AG Use of nk-1 receptor antagonists against benign prostatic hyperplasia
CA2447329C (en) 2001-05-14 2009-07-28 F.Hoffmann-La Roche Ag 1-oxa-3,9-diaza-spiro[5,5]undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor
US20030083345A1 (en) 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
US6667327B2 (en) 2002-02-04 2003-12-23 Hoffmann-La Roche Inc. Pyridine amido derivatives
US6660736B2 (en) 2002-03-27 2003-12-09 Hoffmann-La Roche Inc. Phthalimido derivatives and a process for their preparation
MXPA04010537A (es) 2002-04-26 2005-01-25 Hoffmann La Roche Derivados de isoquinolina.
CN100482638C (zh) 2002-05-29 2009-04-29 弗·哈夫曼-拉罗切有限公司 用作选择性单胺氧化酶b抑制剂的n-酰基氨基苯衍生物
US6951884B2 (en) 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
KR20030095600A (ko) * 2002-06-12 2003-12-24 환인제약 주식회사 펠로디핀을 포함하는 제어방출형 조성물 및 그 제조방법
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
US6846832B2 (en) 2002-08-07 2005-01-25 Hoffman-La Roche Inc. 2,3-dihydro-isoindol-1-one derivatives
PE20050077A1 (es) 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
ES2270154T3 (es) 2002-12-13 2007-04-01 F. Hoffmann-La Roche Ag Derivados de 3h-quinazolin-4-ona.
RU2330022C2 (ru) 2003-01-31 2008-07-27 Ф.Хоффманн-Ля Рош Аг НОВАЯ КРИСТАЛЛИЧЕСКАЯ МОДИФИКАЦИЯ 2-(3, 5-БИС-ТРИФТОРМЕТИЛФЕНИЛ)-N-[6-(1, 1-ДИОКСО-1 λ6-ТИОМОРФОЛИН-4-ИЛ)-4-(4-ФТОР-2-МЕТИЛФЕНИЛ)ПИРИДИН-3-ИЛ]-N-МЕТИЛИЗОБУТИРАМИДА
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics

Also Published As

Publication number Publication date
CA2598762A1 (en) 2006-08-31
ZA200706495B (en) 2008-10-29
EP2281556A1 (en) 2011-02-09
MX2007009571A (es) 2007-09-21
IL185011A0 (en) 2007-12-03
WO2006089674A2 (en) 2006-08-31
RU2007129642A (ru) 2009-03-27
BRPI0606187A2 (pt) 2009-06-09
NZ560232A (en) 2010-11-26
UA90708C2 (ru) 2010-05-25
KR20070094666A (ko) 2007-09-20
US20060193910A1 (en) 2006-08-31
WO2006089674A3 (en) 2007-02-08
US20090304795A1 (en) 2009-12-10
EP1855655A2 (en) 2007-11-21
MA29268B1 (fr) 2008-02-01
NO20074092L (no) 2007-09-04
JP2008531509A (ja) 2008-08-14
CR9292A (es) 2010-04-21
AU2006218193A1 (en) 2006-08-31
TW200640502A (en) 2006-12-01
CN101128189A (zh) 2008-02-20

Similar Documents

Publication Publication Date Title
AR055561A1 (es) Comprimidos con dispersion mejorada de la sustancia farmacologica
UA100866C2 (ru) Продукт твердой дисперсии, который содержит соединения на основе n-арилмочевины
AR054511A1 (es) Una composicion que comprende emtricitabina y tenofovir df granuladas en seco
DK1863812T3 (da) Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler
WO2008007151A3 (en) Processes for preparing pharmaceutical compositions
TN2009000093A1 (en) Pharmaceutical compositions comprising nilotinib or its salt
AR077411A2 (es) Forma de dosificacion farmaceutica solida, con lopinavir y ritonavir, y proceso para su preparacion.
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
NO20064934L (no) Fremgangsmate for fremstilling av et fast, farmasoytisk preparat
EA200900572A1 (ru) Мицеллярные наночастицы с химическими субстанциями
DK1719503T3 (da) Anvendelse af stivelse med fraspaltede sidekæder i ekstrudering/sfæronisering af farmaceutiske pellets
AR052787A1 (es) Proceso para preparar formulaciones de sustancias activas lipofilicas mediante liofilizacion por atomizacion
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
WO2008100240A3 (en) Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
MX2010004291A (es) Producto de dispersion solida de farmacos basados en n-aril urea.
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
CL2007003160A1 (es) Compuestos derivados de piridina; procedimiento de preparacion; formulacion farmaceutica; y uso en el tratamiento de enfermedades tales como trombosis, fibrosis renal, isquemia, entre otras.
NO20054417L (no) Fremgangsmate for fremstilling av farmasoytiske preperater i form av fibratholdige tabletter og de derved fremstilte tabletter
TW200716199A (en) Lozenge production process
AR048756A1 (es) Procedimiento para formar atorvastatina amorfa
AR062626A1 (es) Comprimidos de polimero de poliestireno sulfonato, su preparacion y uso
WO2008021875A3 (en) Pharmaceutical tablets containing a plurality of active segments
CO2017011220A2 (es) Proceso para la fabricación de mezclas de polvo seco
WO2010100658A3 (en) Stable olanzapine tablets and the process for its preparation
EA201800197A1 (ru) Способ получения фармацевтической композиции в форме таблеток, содержащих в качестве действующего вещества абиратерона ацетат, и фармацевтическая композиция

Legal Events

Date Code Title Description
FA Abandonment or withdrawal